Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2023-12-01 | 2023-08-25 |
| Drug Identification Number | 02224623 | 02224623 |
| Brand name | SOFRACORT | SOFRACORT |
| Common or Proper name | Framycetin sulphate, Dexamethasone and Gramicidin Ophthalmic/Otic Solution | Framycetin sulphate, Dexamethasone and Gramicidin Ophthalmic/Otic Solution |
| Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
| Ingredients | GRAMICIDIN DEXAMETHASONE FRAMYCETIN SULFATE | GRAMICIDIN DEXAMETHASONE FRAMYCETIN SULFATE |
| Strength(s) | 0.05MG 0.5MG 5MG | 0.05MG 0.5MG 5MG |
| Dosage form(s) | DROPS | DROPS |
| Route of administration | OTIC OPHTHALMIC OTIC OPHTHALMIC | OTIC OPHTHALMIC OTIC OPHTHALMIC |
| Packaging size | 8 mL bottle | 8 mL bottle |
| ATC code | S03CA | S03CA |
| ATC description | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2023-08-28 | 2023-08-28 |
| Actual start date | 2023-08-28 | |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. Short dated product with November expiry dating is available. |
| Health Canada comments |